Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy

NCT03554486 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Fiasp
DRUG: Novolog

Sponsor

Stanford University

Collaborators

[object Object]